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ABSTRACT: Background. Genetic testing is rapidly becoming an impor-
tant tool in the management of patients with head and neck cancer. As
we enter the era of genomics and personalized medicine, providers
should be aware of testing options, counseling resources, and the bene-
fits, limitations, and future of personalized therapy.
Methods. This article offers a primer to assist clinicians treating patients
in anticipating and managing the inherent practical and ethical chal-
lenges of cancer care in the genomic era.
Results. Clinical applications of genomics for head and neck cancer are
emerging. We discuss the indications for genetic testing, types of testing
available, implications for care, privacy/disclosure concerns, and ethical
considerations. Hereditary genetic syndromes associated with head and
neck neoplasms are reviewed, and online genetics resources are provided.
Conclusion. This article summarizes and contextualizes the evolving
diagnostic and therapeutic options that impact the care of patients with
head and neck cancer in the genomic era. VC 2015 Wiley Periodicals, Inc.
Head Neck 38: E2250–E2258, 2016
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INTRODUCTION
Head and neck cancer is the sixth most common cancer
worldwide.1 Although smoking, alcohol consumption, and
human papillomavirus (HPV) infection are well-
established causes, genetic factors play a crucial role in
tumor initiation, progression, and response to treatment.2
The vast majority of head and neck cancers are sporadic,
with many implicated genetic mutations, making standar-
dized treatment regimens and therapeutic targeting
challenging.
Genetic testing is rapidly becoming an important tool
in the diagnosis and management of patients with head
and neck cancer. What began as basic science initiatives
with only theoretical impact has matured into an exciting
translational arena in which research and clinical care
truly intersect in real time. In our field, we are approach-
ing a watershed. New genes and pathways serving as
potential prognostic indicators or drug targets are being
identified at an increasing rate,3–5 and the therapeutic
applications, while still in development, have the potential
to be groundbreaking.6,7
With such growth, however, come new and unantici-
pated challenges. As we begin to navigate these waters, it
is becoming increasingly important for head and neck
cancer specialists (surgeons, medical oncologists, radia-
tion oncologists, researchers, and others) to learn about
advances in genetics and genomics, the implications of
genetic testing for patient care, and potential ethical
issues. Providers need to become versed in when to test,
when to refer, and where to find genetics resources for
their patients. As exciting as new developments are with
regard to personalized medicine and the genomic frontier,
we need to be ever mindful of the potential unanticipated
harm and ramifications they also create. We may risk
pursuing unnecessary workup and even potential treat-
ment for genetic alterations that may not necessarily
result in disease.8,9 Moreover, in this era of rapidly
changing treatment paradigms, we need to be cognizant
of potential conflict between beneficence (the obligation
to do good) with autonomy (allowing for patient self-
determination and avoiding coercion). Given our commit-
ment to improve care and the allure of novel therapies,
we must carefully balance goals and limit harms while
respecting patient choices.10
Head and neck cancer specialists will encounter spe-
cific practical and ethical issues in all phases of genetic
testing and personalized medicine delivery. This will
invariably include: (1) initial determination of the indica-
tions for and type of genetic testing; (2) provision of
genetic counseling so that patients can make an informed
choice; (3) interpretation and disclosure of findings; (4)
translating results into clinical care; and (5) advising
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patients, when indicated, about disclosure of results to at-
risk relatives. This article is designed as a primer to assist
clinicians treating patients with head and neck cancer in
anticipating and managing these challenges as we enter
the genomic era of cancer care.
WHO, WHY, AND WHEN TO TEST
Indications for testing
The first fundamental question most head and neck can-
cer providers will encounter regards which patients merit
genetic testing. The primary indications for testing
include the identification of tumor mutations to direct tar-
geted therapy, and recognizing germline mutations that
may put patients and/or relatives at risk for head and
neck cancers. Most commonly, patients will present with
a biopsy-confirmed malignancy of the head and neck.
Some patients may express interest in, and/or be candi-
dates for, observational and/or interventional research tri-
als. In these cases, genetic testing is usually performed to
identify somatic mutations in the tumor tissue to inform
correlative research exploring prognostic predictors and/or
therapeutic targets.11 Patients with specific phenotypes or
clinical presentations may be targeted for such testing in
an effort to identify potentially novel oncogenic drivers
or lost suppressors.
A minority of patients might have previously undergone
germline genetic testing through blood sample analysis,
possibly because of a positive personal and/or family his-
tory suggestive of a hereditary syndrome (such as multi-
ple affected individuals, early age of onset, and/or
multiple primary cancers). Given the possibility of mosai-
cism, tumor testing may also be performed in patients
with a suspected hereditary cancer syndrome and negative
germline testing results. Rare, heritable conditions
increasing the risk of head and neck cancers are listed in
Table 1.12
Other patients may have been referred because of sec-
ondary (also known as incidental) genetic test results that
might imply a predisposition for head and neck cancer;
these are discussed in depth in ensuing sections. The
counseling process for such patients will be fundamen-
tally different compared to a patient with a known or sus-
pected malignancy, and will need to be tailored
accordingly.
Testing options
Physicians have a variety of genetic testing options.
Genetic testing to inform the clinical prognosis and/or
guide treatment of head and neck cancer is not currently
routinely performed. However, testing to identify or
screen for targetable mutations is increasingly being used
in the research setting. Testing modalities (even for the
same gene/condition) vary widely and therefore selection
of the specific genetic test, methodology, and laboratory
is important. Testing options can range from single gene
testing to gene panels to whole exome or whole genome
sequencing. Whole exome sequencing refers to sequenc-
ing the protein-coding exons in a patient’s genome,
whereas whole genome sequencing involves sequencing
coding and noncoding regions of the genome.21 Analysis
of genes can include gene sequencing, mutation panels,
deletion/duplication analysis, or testing for a known fami-
lial gene mutation. Choosing a specific test incorporates
clinical judgment and treatment goals. For example, sin-
gle gene testing for RET mutations is appropriate for a
patient with a family history of hereditary medullary thy-
roid cancer, whereas one might use whole exome/genome
or gene panel testing to identify potential targetable muta-
tions in a patient with advanced head and neck squamous
cell carcinoma (HNSCC) refractory to current care.
Some genetic testing laboratories offer the option of
banking DNA or RNA samples from a patient. In situa-
tions in which the patient has limited lifespan and genetic
testing is not available, too costly, or of limited sensitiv-
ity, the head and neck cancer provider can offer DNA
and RNA banking for future genetic study.22
Tumor versus germline mutations
Clinicians must clearly distinguish the difference
between mutations identified in tumor specimens versus
germline mutations. Sequencing tumor DNA can yield a
number of mutations that generally will not be found in
the individual’s germline tissue.23 Indeed, recent studies
in HNSCC have identified an average of 140 mutated
genes per tumor genome.5 Counseling patients regarding
the implications of mutated tumor genes (which are likely
not mutated in their germline cells) should include cav-
eats that such mutations are not heritable, and may have
uncertain implications for prognosis and treatment.
Although whole exome or genome sequencing is not
currently incorporated in the standard of care for treat-
ment of head and neck cancers, it is increasingly being
used in research settings, primarily to identify prognostic
predictors and candidate genes for drug targeting. In these
instances, clinicians must clearly distinguish the differ-
ence between mutations identified in tumor specimens
versus germline mutations. Genetic sequencing of malig-
nant tumor cells involves studying biopsy tissue or an
extirpated surgical specimen, and identifying mutations
that may contribute to tumorigenesis, predict prognosis,
and/or represent potential therapeutic targets. In order to
identify unique oncogenic mutations, germline genomic
DNA is sequenced and used as a background from which
mutational changes in tumors are identified. Sequencing
germline samples involves nonpathologic cells from
patients (usually adjacent normal tissue, or blood).3,4 Usu-
ally, germline DNA is not examined for mutations, but
rather is used as the “normal” control.23 Thus, investiga-
tors may be blinded to the germline mutational data. This
means of analysis can protect patients from secondary
findings, and providers from needing to interpret such
data, as discussed below. In the rare instances that heredi-
tary head and neck cancer is suspected in a patient, germ-
line genomic DNA may be sequenced in an unblinded
fashion. Alternatively, patient genomes can be compared
against a reference genome database of pooled sequenced
genomes24 to account for potential known benign and
pathogenic variants.25
Direct to consumer testing
Direct-to-consumer (DTC) companies offer genetic
screening, which include genes known to be associated
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with cancers.26 These tests are ordered by individuals via
the internet and usually without the involvement of a phy-
sician. These companies identify single nucleotide poly-
morphisms (SNPs), and offer proprietary assessments on
risk for a number of diseases based upon these findings,
including the risk for cancer. Risk assessment and disease
prediction based on SNPs is of limited clinical utility, and
could result in misinformation or false reassurance. Patients
may present to clinicians with such preinterpreted data and
have ensuing questions and concerns. Knowledge of the
limitations and means of interpretation will be important
for the provider tasked with discussing DTC results with
these patients. It is important to inform patients that these
DTC tests are not considered standard of care, do not have
external quality control, are not ordered in genetics clinics,
and may have limited clinical validity.27–30
In 2013, the Food and Drug Administration (FDA)
issued a cease and desist order against 23andme because
of concerns with the accuracy and validity of their inter-
pretations with clinical implications, including cancer
risk.27 The American College of Medical Genetics and
Genomics (ACMG) and the National Society of Genetic
Counselors recommend involvement of a geneticist or
genetic counselor to discuss issues regarding indications
for and interpretation of testing.28,29 This includes discus-
sing the limitations of results, having easy to understand
information available, and ensuring proper laboratory
accreditation.28,30 Thus, DTC services remain in flux and
have significant limitations about which physicians should
inform patients accordingly.
Pre-test counseling
Regardless of clinical context, it is important to have a
clear and definitive consent process in which the implica-
tions of testing are clearly addressed.31,32 Genetic test
results have broad implications. Issues to discuss include
testing options, the likelihood of identifying the gene
mutation(s) and whether additional testing might be
needed, the types of results and implications, cost of test-
ing, and privacy and insurance considerations. Explicit
and comprehensive pretest counseling has been strongly
recommended by the American Society of Clinical Oncol-
ogy as an integral component of the consent process.32
Head and neck cancer specialists may see patients who
either have (or are at increased risk for) cancer and need
to consider genetic testing and/or have results interpreted.
Debate exists whether any care provider may interpret and
provide counseling on results of genetic testing, or whether
this should be a role reserved specifically for geneticists
and genetic counselors.33 There have been reports of
adverse outcomes with clinicians without dedicated training
providing cancer genetics counseling to patients.9
The wide array of testing options can be overwhelming
for patients and providers alike. Moreover, insurance cover-
age of genetic testing is often a major hurdle for patients,
and costs of such tests may be exorbitant. Given the exper-
tise needed to select the specific gene(s), testing methodol-
ogy and laboratory, as well as to provide accurate result
interpretation, it is generally recommended that patients be
referred to a cancer genetics clinic, an oncology clinic with a
genetic counselor, or a specialist with genetics expertise.
Resources for finding providers with genetics expertise and
TABLE 2. Online genetic resources.
Online Searchable Databases of Genetic Specialists and
Genetics Clinics
 American Board of Genetic Counseling (“Find a Certified Genetic
Counselor”)
 American College of Medical Genetics and Genomics (“Find
Genetic Services”)
 GeneClinics (GeneTests website, follow link to “Clinics,” includes
clinics in other countries)
 National Cancer Institute – Cancer Genetics Services Directory
 National Society of Genetic Counselors (“Find a Genetic
Counselor”)
 Orphanet (clinics in Europe)
Information about Genetic Conditions for Healthcare
Professionals
 GeneReviews
 MedGen (National Center for Biotechnology Information [NCBI])
 National Cancer Institute: PDQ Cancer Information Summaries –
Genetics
 Online Mendelian Inheritance in Man (OMIM)
 Orphanet
Information about Genetic Conditions, Genetic Testing, and
Support Group Resources for Patients
 Genetics Home Reference
 Genetic Alliance (“DiseaseInfo Search” link to find support groups
for genetic conditions)
 Genetic Alliance UK
 Genetic and Rare Diseases Information Center (has phone option)
 National Organization for Rare Disorders
 Orphanet (support group resources in Europe)
Fact Sheets/Brochures about Patterns of Inheritance
 Centre for Genetics Education (“Genetics Fact Sheets” link,
“Multilingual Resources” link)
 EuroGenTest (“Patient Leaflets” link; multiple languages)
 Genetic Alliance UK (“Information Centre” link; multiple
languages)
Genetic Testing (insurance implications information)
 Genetic Information Nondiscrimination Act (GINA): www.ginahelp.
org
 National Human Genome Research Institute
 Genetic Discrimination
 Genome Statute and Legislative Database
 HumGen (international database)
Genetic Testing (general information)
 Genetics Home Reference (“Handbook” link)
 National Cancer Institute
 Fact Sheet: Genetic Testing for Hereditary Cancer Syndromes
 National Human Genome Research Institute
 Frequently Asked Questions about Genetic Testing
 “Genetic Testing: What it Means for your Health and for your
Family’s Health
Online Searchable Databases of Genetic Tests
 Genetic Testing Registry – NCBI (GTR)
 GeneTests
 Eurogentests (Clinical Utility Gene Cards, laboratories in Europe)
 Orphanet (laboratories in Europe)
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other genetics resources for patients and providers are
included in Table 2.3434 Telephone or internet-based genetic
counseling services are also available, which may provide an
alternative avenue for patients with limited geographic
access.
Privacy concerns
Patients may have concerns about the privacy of genetic
information and the implications that the results could have
for their insurance coverage. The Health Insurance Portabil-
ity and Accountability Act (HIPAA) of 1996 specifically
incorporates genetic information in its protection of patients’
clinical data.35 The HIPAA/Health Information Technology
for Economic and Clinical Health Act was updated in 2013
to confirm that a person’s genetic information is indeed
considered protected health information, and cannot be dis-
closed without a patient’s explicit written consent.36 Genetic
information in these cases includes family medical history,
and individual and familial genetic test results.
In 2008, the Genetic Information Nondiscrimination
Act (GINA) was passed into law. The purpose of this act
was to prevent discrimination based upon one’s genetic
information.37 The act prevents health insurance compa-
nies (private and public) from being able to request
genetic testing as a condition for eligibility or insurability,
and prevents discrimination in premiums based upon
known genetic test results. Additionally, the law prohibits
employers from requesting or using genetic information
for employment decisions. Notably, GINA does not apply
to businesses with <15 employees. The Affordable Care
Act, passed in 2010, reinforced these principles; it does
not allow health insurers to vary insurance rates or cover-
age because of preexisting conditions, including genetic
disease or results.38 GINA has been strongly enforced,
with the U.S. Equal Employment Opportunities Commis-
sion recently reaching 2 settlements against companies
requesting family medical information on the grounds
that patients’ genetic rights were being violated.39,40
Of note, life, long-term care, and disability insurance are
currently not protected; patients with known gene muta-
tions may have more difficulty obtaining such insurance
policies and should be counseled accordingly before test-
ing.37 Information on GINA and legislation regarding the
use of genetic information in insurance and employment
can be accessed through the resources listed in Table 2.
Consent allowing for the future research use of banked
specimens in the clinical or research arena may raise
unforeseen privacy concerns in ensuing years. These pri-
vacy issues are an integral component of the pretest
consent process. As such, patients should receive assurance
regarding how samples and genetic test results will be pro-
tected, and how the information can and cannot be shared
and utilized. Privacy can be of particular concern with
regard to DTC testing, as private companies are not neces-
sarily health providers who are bound by HIPAA, and
may not have explicit policies protecting collected data.30
Testing children
It is important to carefully consider circumstances sur-
rounding testing of children. Although head and neck cancer
is generally an adult disease, genetic conditions may place
children at risk for head and neck cancers that require early
detection and intervention (eg, medullary thyroid carci-
noma; Table 1). The American Academy of Pediatrics and
ACMG issued a joint statement with the overriding goal of
prioritizing the best interests and care of the infant or child,
which supports genetic testing only when anticipated results
will affect clinical management before adulthood.41
Interpretation and disclosure of results
When contemplating genetic testing in head and neck
cancer, pretest counseling can proactively address possi-
ble results and their implications. The ACMG recently
discussed addressing variants and mutations encouraging
the use of standardized terminology, including
“pathogenic,” “likely pathogenic,” “uncertain signifi-
cance,” “likely benign,” and “benign” to convey certainty
and risk of disease.42 These labels should be used when
disclosing such variants.
If exome or whole genome sequencing is being done, an
increasingly important and complex issue to address is how
to deal with the identification of secondary (incidental)
findings of pathogenic mutations or variants of unknown
significance for conditions unrelated to the indication for
testing. In broad strokes, the consensus among most experts
favors the disclosure of incidentally found mutations only
when (1) they have clinical significance, (2) patients have
consented to receive the information, and (3) they are clini-
cally actionable (impacting screening and treatment deci-
sions).31,43 Although this makes good sense in theory, the
significant challenge arises in determining which tests and
test results satisfy the first and third stipulations.
Clinically significant incidental mutations
The ACMG provided a controversial recommendation
in 2013 regarding disclosure of secondary (incidental)
findings. They published a list of 56 genes with potential
clinically actionable impact for which they recommended
screening and disclosure in every instance in which a per-
son undergoes germline genomic sequencing.44 Twenty-
three of these genes are related to cancer risk. Of particu-
lar interest to the head and neck provider are genes for
medullary thyroid cancer (RET, MEN1), hereditary para-
ganglioma (SDHD, SDHAF2, SDHC, and SDHB), neuro-
fibromatosis 2 (NF2), and Li–Fraumeni syndrome (TP53),
among others (Table 1).
Subsequently, there has been intense debate on whether
mandating characterization of these 56 genes in genomic
studies infringes upon patient autonomy, as many other
organizations, including the President’s Commission on
Bioethics, have emphasized respecting a patient’s right not
to know.45–48 Some suggest that by mandating screening
when a patient is undergoing genomic testing (thereby
denying one’s right not to know), patient autonomy is
compromised in order to achieve a presumably beneficent
objective. Others might counter that if the germline DNA
is being analyzed, it behooves clinicians and researchers to
report on relevant findings, and potentially provide care
options.49 Similar ethical issues frequently arise in other
arenas of clinical care, such as incidental findings on
imaging,50 with arguments for specific instances for disclo-
sure of “relevant,” albeit unanticipated, results. In response
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to concerns raised in the genetics community, the ACMG
softened its stance, with updated recommendations allow-
ing for an “opt-out” option before sequencing.51
Specific pretest discussion reviewing patient preferen-
ces regarding disclosure of both anticipated and secondary
findings is important. It remains important to inform
patients about the ACMG recommendations and have dis-
cussions concerning the benefits and risks of screening
these 56 genes, and potentially other genes as well.
Broadly speaking, explicit benefits include identifying
conditions for which the patient is at increased risk, possi-
ble disease prevention through screening or early treat-
ment (eg, prophylactic thyroidectomy in patients with
clinically occult RET mutations), and the ability to inform
other at-risk relatives. Risks include identifying a muta-
tion that has unknown penetrance in a low-risk popula-
tion, finding variants of unknown significance with
unclear clinical implications, and the emotional impact of
learning about risks for other conditions when already
dealing with cancer. As the field of genomic research
evolves, the knowledge base will expand, and the impli-
cations of such findings (and the number of genes for
which clinically relevant information becomes available)
will only grow exponentially.
Variants of unknown significance
Genomic testing uncovers a high number of SNPs and
variants of unknown significance (VUS).52 The vast
majority of SNPs are thought to be nonpathologic allelic
variants.53 Of those that have some association with
increased cancer risk, the impact of individual SNPs is
believed to be quite low, with odds ratios ranging from
1.2 to 1.6.54 VUS are identified at a high frequency, par-
ticularly in HNSCCs, in which these tumors average 140
genes containing at least 1 somatic mutation,5 and with
many of these mutations unique and previously unre-
ported. Consequently, the functional outcomes of these
mutations are largely unknown.
Interpretation and disclosure of SNPs and VUS is a
complex process. Reporting all of these variants will
obviously be overwhelming and difficult to interpret for
providers, let alone patients. Additionally, the clinical
utility of these findings is limited. Unlike in cases of a
highly penetrant pathological mutation, any consideration
regarding disclosure of information regarding SNPs
should be prefaced by an acknowledgment of their limited
clinical utility. It should be clearly conveyed during pre-
test counseling and disclosure to patients that a VUS truly
has unknown significance, should not be equated to a
pathogenic mutation, and may be reclassified as more is
learned in the future. As such, disclosure of VUS identi-
fied through genomic sequencing in genes unrelated to
the primary disease process is not routinely performed. In
instances when the clinician and patient agree to disclo-
sure, these variants should be classified based on suspi-
cion of pathogenicity, as described above.42
Clinically actionable findings
When considering disclosure, a key debate centers on
what makes a particular finding “clinically actionable.”8,43
Offit et al55 highlighted the importance of distinguishing
clinical diseases with high versus low gene penetrance,
and actionable versus nonactionable results. One must
consider, however, that as our ability to treat disease rap-
idly evolves, what is not “clinically actionable” at this
time may very well become so in the near future. Thus,
continual reassessment of our knowledge base, clinical
recommendations, and disclosure should be performed.
Patients should also be encouraged to remain in touch
with their providers to continually reassess the implica-
tions of their clinical data.
Specifically, clinically actionable results are those for
which an intervention may be performed to screen for
pathology, prevent or eliminate disease, or improve
patient outcomes. For example, neoplasms with discrete
genetic causes impacting the head and neck include med-
ullary thyroid cancer (RET). For patients with germline
RET mutations, American Thyroid Association guidelines
have strict criteria for mutation-specific screening and
management, including prophylactic thyroidectomy in
certain cases.14 As another example, patients with heredi-
tary paragangliomas (SDHAF2, SDHD, SDHC, and
SDHB) have specific indications for imaging, screening
family members, and intervention.16
Some diseases with genetic associations may be clini-
cally relevant, but not clinically actionable. The concept
is illustrated by using Huntington disease as a paradigm.
Informing a patient about a risk for Huntington disease
does not lead to a change in clinical outcome but has sig-
nificant prognostic and psychological ramifications. Some
patients would request such results, whereas others would
never want to know. International guidelines detail the
comprehensive pretest counseling, informed consent, and
in-person disclosure of genetic test results for Huntington
disease.56
The duty to warn
Our discussion to date has been patient-centric, and
rightfully so; the primary concern in all such cases is the
rights and well-being of the individual who has entrusted
his or her health to your care. However, genetic informa-
tion necessarily transcends the doctor-patient dyad. As
such, the perspective and rights of family members also
require attention and discussion. There is an inherent con-
flict between patients’ rights to privacy and ownership of
information, with the duty to share relevant facts with
their family. In the majority of cases, patients who are
appropriately counseled will agree to involve family as is
necessary in order to inform their own health care
choices. However, this may not always hold true. Hence,
clinicians may be placed in situations in which they must
weigh the relative importance of 1 patient’s autonomy
and privacy versus the duty to shepherd the interests of
their relatives.57–59
Pretest counseling should include discussing the signifi-
cance and implications of results for family members.
However, what should be done in the rare cases in which
a patient’s request conflicts with familial best interests
despite adequate counseling? The American Medical
Association and American Society of Clinical Oncology
do not sanction physicians to override patient confiden-
tiality in order to warn family members.60,61 The Ameri-
can Society of Human Genetics advocates that physicians
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have the responsibility to warn at-risk family members
only if the potential harm is imminent and serious, and
treatment or prevention options are available.59 The legal
basis for the latter position is an extrapolation of the
well-known Tarasoff ruling (1976),62 in which physicians
can override confidentiality and are obligated to warn at-
risk third parties of imminent danger. Briefly, in the Tar-
asoff case, a psychologist treated a patient who expressed
intent to kill a third party; no warning or alert was given
to the intended victim, and the patient ultimately carried
out his plan. The California Supreme Court subsequently
established legal precedent for a clinician’s duty to warn
third parties against overt threats, clarifying that danger to
others may override confidentiality.
Lawsuits have been filed in cases in which physicians
did not explicitly warn family members of their risk of
developing a heritable cancer. Pate v Threlkel63 (1995) is
of particular interest to head and neck providers, as this
case involved a patient whose mother was previously
treated for medullary thyroid carcinoma. The plaintiff
developed the disease years later, and filed suit claiming
that her cancer could have been avoided with earlier
screening and prophylactic thyroidectomy. The court
ruled in favor of the defendant, claiming that the physi-
cian’s duty to warn was sufficiently fulfilled by discus-
sing potential risks affecting family members with the
patient, rather than seeking family members directly.
Another relevant case, Safer v Estate of Pack64 (1996),
offers a conflicting interpretation. Involving a case of
familial adenomatous polyposis, the court held that a
physician’s duty to warn family members may not be sat-
isfied just by alerting the patient, but rather a physician
may need to take extra steps to warn such individuals
directly. Ultimately, the New Jersey appellate court sided
with the defendant. Although a patient’s HIPAA-
protected confidentiality remains important, in this
instance, the court ruled that disclosure was justified.
As evidenced by conflicting professional guidelines and
case law, the ethics and legalities governing the disclo-
sure of genetic information to family members remains
an extremely complex issue. The interested reader is
referred to more robust discussions of this topic as further
details are beyond our scope.55,57 In summary, pretest dis-
cussions will necessarily include counseling regarding
potential impact upon family members, and clinicians are
behooved to consider the impact of information on indi-
viduals other than the patient sitting in front of them. In
cases involving conflicting obligations concerning access
to information and privacy, ethics and/or legal consulta-
tion is strongly encouraged.
Translating genomics into treatment
As we enter an era of personalized medicine and tar-
geted therapies, genomic characterization is playing an
increasingly larger role in how we individualize cancer
treatment.65–67 It remains important to note that personal-
ized medicine and genomic testing are currently not
standard of care in head and neck cancer management.
As it now stands, there is no genomic signature that influ-
ences the routine guideline-based treatment of HNSCC.
In fact, to date, the FDA has only approved 19 compan-
ion diagnostic tests for use in the treatment of cancer.68
However, genomic studies are an instrumental component
of translational research programs, and will likely become
integrated into routine clinical care in the near future as
the field advances. With regard to targeted therapies,
although cetuximab is currently the only FDA-approved
targeted agent in the management of HNSCC,69,70 numer-
ous exciting targeted therapies are in various stages of
development.6 There have been significant advances in
targeted therapy against thyroid cancer. Sorafenib (Nexa-
var) and lenvatinib (Lenvima) have shown survival bene-
fit and are FDA-approved for locally recurrent or
metastatic differentiated thyroid cancer refractory to
radioiodine therapy.71,72 Additionally, there are FDA-
approved targeted therapeutics (vandetanib [Caprelsa] and
cabozantinib [Cometriq]) for unresectable, progressive, or
metastatic medullary thyroid cancer.73,74
Even in the face of encouraging preclinical data and/or
extrapolated results from other cancers, counseling
patients for genomic screening to select targeted therapy
needs to emphasize the investigational nature of these
studies. A high level of caution is necessary before offer-
ing an unproven targeted agent based upon genomic find-
ings. Conflict may arise in situations in which a patient
has identified mutations in potentially targetable genes,
with agents with unproven responses in head and neck
cancers. The value of attempting novel therapies versus
the standard of care must be carefully weighed in such
cases. Our opinion is that any use of genomic data to
inform cancer-directed therapy in the head and neck
(either with curative or palliative intent) should be
reserved for patients meeting strict inclusion criteria, and
governed by a clear experimental clinical research proto-
col with institutional review board oversight, with a com-
prehensive informed consent process.
We feel that this is especially critical in genetically
complex cancers, such as smoking and alcohol-related
HNSCC. Unfortunately, when targeted monotherapies fail
in precision medicine clinical trials, the recurrent tumors
can be highly aggressive and rapidly lethal. Because of
the complex array of disruptive genomic events in
HNSCC, it is unlikely that individual targeted monother-
apy with currently available agents will produce signifi-
cant response. In these cases, it may be appropriate to
consider ongoing clinical trials of complex combinations
targeting multiple drivers that have been evaluated in
phase I safety trials.
Another important factor in consideration of HNSCC
treatment is HPV status. It is well established that HPV-
associated HNSCCs have a better prognosis than their
HPV-negative counterparts, and consist of a different epi-
demiological group (HPV vs smoking and alcohol-related
tumors).75 Moreover, HPV-positive tumors seem to have
a lighter mutational burden in comparison to HPV-
negative HNSCCs.5,76 In light of these significant muta-
tional, biologic, and outcome differences, discrete person-
alized treatment paradigms may be developed based in
part upon HPV status.6
In general, the ideal patients for early phase trials
involving targeted personalized therapy may include those
with recurrent/persistent/incurable disease who have not
responded to current standard of care, or those with rare
tumors for which no standard treatment may exist.
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We strongly encourage head and neck cancer clinicians
and patients alike to consider enrolling in ongoing trials
(both observational and interventional) within dynamic
multidisciplinary translational research programs. Such
involvement is critical in guiding further care because of
the nascent nature of the field and need for more robust
data designed to understand the investigational nature of
targeted therapy based upon genomic results.
Multidisciplinary involvement from head and neck sur-
geons, geneticists, medical and radiation oncologists, and
translational biologists is integral to developing personal-
ized treatment paradigms. Genomic data may be dis-
cussed at Precision Medicine Tumor Boards to identify
potential trials using targeted agents in which the patient
may enroll. The National Cancer Institute and many terti-
ary care centers throughout the country are creating such
programs using genetic information to apply personalized
targeted therapy to selected cancers.77,78 Their growing
relevance speaks to the excitement of cancer care in the
era of genomics.
It should be clearly explained during the consent pro-
cess to patients enrolling in early phase clinical trials that
the primary goal of these trials is to establish drug dosing,
feasibility of treatment, and to document adverse effects.
Although patients, clinicians, and researchers alike will
necessarily be hopeful for clinical response or cure, this
is NOT necessarily the primary outcome, nor the reason
such early phase trials were designed. Such patients are
extremely vulnerable to therapeutic misconception (the
misunderstanding about the difference in goals between
clinical research vs treatment).79 This point should be
stressed as patients have been shown to be prone to have
overly optimistic expectations of beneficial results from
investigational treatments or treatment therapies for
advanced cancer despite rigorous informed consent proc-
esses.80–82 Open discussion of potential conflicts of inter-
est and the discrete goals of patients, families, clinicians,
and researchers should be openly disclosed to identify
potential areas of contention or confusion.
CONCLUSION
The era of personalized medicine has arrived. No lon-
ger do cancer genomic researchers study anonymous cells
devoid of a corresponding patient. Likewise, head and
neck cancer specialists cannot ignore the rapid advances
made in laboratories across the world, as these findings
will fundamentally shape our interactions at the bedside.
In this setting, clinicians treating head and neck cancer
must become familiar with genomic medicine. As
genomic advances inform head and neck oncology, guide-
lines on the use of and ethics inherent to genetic testing
in diagnosis and management will need to be developed
and take into account the constantly evolving nature of
the field. The ethical issues arising from the concept of
genomics and personalized medicine include conflicts
between autonomy and beneficence, communication and
management of secondary findings, how to appropriately
design and conduct trials with individualized targeted
medications, privacy concerns, and considering the duty
to warn. Head and neck cancer specialists must become
literate in the language, scope, and practice of personal-
ized medicine resources, both to remain at the forefront
of cancer treatment as well as to continue to support the
best interests and rights of our patients.
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